Drug Profile
APD 405
Alternative Names: APD405Latest Information Update: 13 Jun 2022
Price :
$50
*
At a glance
- Originator Acacia Pharma
- Class Antiemetics
- Mechanism of Action Dopamine D2 receptor antagonists; Serotonin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Postoperative nausea and vomiting
Most Recent Events
- 09 Jun 2022 Acacia Pharma has been acquired by Eagle Pharmaceuticals
- 17 Dec 2009 Discontinued - Phase-II for Postoperative nausea and vomiting in Europe (IV)
- 17 Dec 2009 Discontinued - Phase-II for Postoperative nausea and vomiting in USA (IV)